TY - JOUR
T1 - Impact of a donor source on adult philadelphia chromosome-negative acute lymphoblastic leukemia
T2 - A retrospective analysis from the adult acute lymphoblastic leukemia working group of the japan society for hematopoietic cell transplantation
AU - Nishiwaki, S.
AU - Miyamura, K.
AU - Ohashi, K.
AU - Kurokawa, M.
AU - Taniguchi, S.
AU - Fukuda, T.
AU - Ikegame, K.
AU - Takahashi, S.
AU - Mori, T.
AU - Imai, K.
AU - Iida, H.
AU - Hidaka, M.
AU - Sakamaki, H.
AU - Morishima, Y.
AU - Kato, K.
AU - Suzuki, R.
AU - Tanaka, J.
N1 - Funding Information:
This study was supported in part by the Japan Leukemia Research Fund grant to SN, in part by the Research on Allergic Disease and Immunology (Health and Labor Science Research Grant), the Ministry of Health, Labor and Welfare of Japan to KM and YM, and in part by a Japanese Grant-in-Aid for Scientific Research to JT [no specific grant numbers].
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2013/6
Y1 - 2013/6
N2 - Background: We aimed to clarify the impact of the donor source of allogeneic stem cell transplantation (allo-SCT) on Philadelphia chromosome-negative acute lymphoblastic leukemia [Ph(-) ALL] with focus on cord blood (CB). Patients and methods: We retrospectively analyzed data of 1726 patients who underwent myeloablative allo-SCT for adult Ph(-) ALL. The sources of the allo-SCT were related donors (RD; N = 684), unrelated donors (URD; N = 809), and CB (N = 233). Results: Overall survival (OS) in patients after CB allo-SCT in first complete remission (CR1) was comparable with that after RD or URD allo-SCT (RD: 65%, URD: 64% and CB: 57% at 4 years, P = 0.11). CB was not a significant risk factor for relapse or non-relapse mortality as well as for OS in multivariate analyses. Similarly, the donor source was not a significant risk factor for OS in subsequent CR or non-CR (RD: 47%, URD: 39% and CB: 48% in subsequent CR, P = 0.33; RD: 15%, URD: 21% and CB: 18% in non-CR, P = 0.20 at 4 years). Conclusion: Allo-SCT using CB led to OS similar to those of RD or URD in any disease status. To avoid missing the appropriate timing, CB is a favorable alternative source for adult Ph(-) ALL patients without a suitable RD or URD.
AB - Background: We aimed to clarify the impact of the donor source of allogeneic stem cell transplantation (allo-SCT) on Philadelphia chromosome-negative acute lymphoblastic leukemia [Ph(-) ALL] with focus on cord blood (CB). Patients and methods: We retrospectively analyzed data of 1726 patients who underwent myeloablative allo-SCT for adult Ph(-) ALL. The sources of the allo-SCT were related donors (RD; N = 684), unrelated donors (URD; N = 809), and CB (N = 233). Results: Overall survival (OS) in patients after CB allo-SCT in first complete remission (CR1) was comparable with that after RD or URD allo-SCT (RD: 65%, URD: 64% and CB: 57% at 4 years, P = 0.11). CB was not a significant risk factor for relapse or non-relapse mortality as well as for OS in multivariate analyses. Similarly, the donor source was not a significant risk factor for OS in subsequent CR or non-CR (RD: 47%, URD: 39% and CB: 48% in subsequent CR, P = 0.33; RD: 15%, URD: 21% and CB: 18% in non-CR, P = 0.20 at 4 years). Conclusion: Allo-SCT using CB led to OS similar to those of RD or URD in any disease status. To avoid missing the appropriate timing, CB is a favorable alternative source for adult Ph(-) ALL patients without a suitable RD or URD.
KW - Allogeneic stem cell transplantation
KW - Cord blood
KW - Donor source
KW - Philadelphia chromosome-negative acute lymphoblastic leukemia
UR - http://www.scopus.com/inward/record.url?scp=84878438842&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878438842&partnerID=8YFLogxK
U2 - 10.1093/annonc/mds655
DO - 10.1093/annonc/mds655
M3 - Article
C2 - 23372050
AN - SCOPUS:84878438842
VL - 24
SP - 1594
EP - 1602
JO - Annals of Oncology
JF - Annals of Oncology
SN - 0923-7534
IS - 6
ER -